ProfileGDS4814 / ILMN_1738552
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 48% 40% 60% 17% 51% 34% 55% 43% 43% 36% 17% 34% 33% 28% 48% 53% 46% 46% 56% 23% 31% 13% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)49.946248
GSM780708Untreated after 4 days (C2_1)47.783440
GSM780709Untreated after 4 days (C3_1)55.642160
GSM780719Untreated after 4 days (C1_2)42.809317
GSM780720Untreated after 4 days (C2_2)50.954251
GSM780721Untreated after 4 days (C3_2)46.379934
GSM780710Trastuzumab treated after 4 days (T1_1)52.609155
GSM780711Trastuzumab treated after 4 days (T2_1)48.417943
GSM780712Trastuzumab treated after 4 days (T3_1)48.453243
GSM780722Trastuzumab treated after 4 days (T1_2)46.935636
GSM780723Trastuzumab treated after 4 days (T2_2)42.934917
GSM780724Trastuzumab treated after 4 days (T3_2)46.513434
GSM780713Pertuzumab treated after 4 days (P1_1)46.104933
GSM780714Pertuzumab treated after 4 days (P2_1)45.239828
GSM780715Pertuzumab treated after 4 days (P3_1)49.857448
GSM780725Pertuzumab treated after 4 days (P1_2)51.700453
GSM780726Pertuzumab treated after 4 days (P2_2)49.220446
GSM780727Pertuzumab treated after 4 days (P3_2)49.241546
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)52.868956
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)44.21223
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.778831
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.956413
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.433134